128 related articles for article (PubMed ID: 29498772)
21. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453
[TBL] [Abstract][Full Text] [Related]
22. C-kit Asp-816-Val mutation analysis in patients with mastocytosis.
Verzijl A; Heide R; Oranje AP; van Schaik RH
Dermatology; 2007; 214(1):15-20. PubMed ID: 17191042
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
[TBL] [Abstract][Full Text] [Related]
24. Genotype and phenotype analysis of patients with pediatric cutaneous mastocytosis, especially wild-type KIT patients.
Arase N; Wataya-Kaneda M; Murota H; Nakagawa Y; Yamaoka T; Itoi-Ochi S; Hirayasu K; Arase H; Fujimoto M; Katayama I
J Dermatol; 2020 Apr; 47(4):426-429. PubMed ID: 32077120
[TBL] [Abstract][Full Text] [Related]
25. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
[TBL] [Abstract][Full Text] [Related]
26. [Cutaneous mastocytosis].
Flageul B
Rev Prat; 2006 Oct; 56(16):1745-51. PubMed ID: 17315498
[TBL] [Abstract][Full Text] [Related]
27. CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2/p27
Zhang F; Liu X; Chen C; Zhu J; Yu Z; Xie J; Xie L; Bai H; Zhang Y; Fang X; Gu H; Wang C; Weng W; Zhang CC; Chen GQ; Liang A; Zheng J
Haematologica; 2017 Apr; 102(4):707-718. PubMed ID: 28126968
[TBL] [Abstract][Full Text] [Related]
28. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
29. Aldh2 Attenuates Stem Cell Factor/Kit-Dependent Signaling and Activation in Mast Cells.
Kim DK; Cho YE; Song BJ; Kawamoto T; Metcalfe DD; Olivera A
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835486
[TBL] [Abstract][Full Text] [Related]
30. M-COPA suppresses endolysosomal Kit-Akt oncogenic signalling through inhibiting the secretory pathway in neoplastic mast cells.
Hara Y; Obata Y; Horikawa K; Tasaki Y; Suzuki K; Murata T; Shiina I; Abe R
PLoS One; 2017; 12(4):e0175514. PubMed ID: 28403213
[TBL] [Abstract][Full Text] [Related]
31. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior.
Büttner C; Henz BM; Welker P; Sepp NT; Grabbe J
J Invest Dermatol; 1998 Dec; 111(6):1227-31. PubMed ID: 9856847
[TBL] [Abstract][Full Text] [Related]
32. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
Shivakrupa R; Bernstein A; Watring N; Linnekin D
Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
[TBL] [Abstract][Full Text] [Related]
33. Distinct signalling pathways for mutated KIT(V560G) and KIT(D816V) in mastocytosis.
Chan IJ; Kasprowicz S; Tharp MD
Clin Exp Dermatol; 2013 Jul; 38(5):538-44. PubMed ID: 23777495
[TBL] [Abstract][Full Text] [Related]
34. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.
Bodemer C; Hermine O; Palmérini F; Yang Y; Grandpeix-Guyodo C; Leventhal PS; Hadj-Rabia S; Nasca L; Georgin-Lavialle S; Cohen-Akenine A; Launay JM; Barete S; Feger F; Arock M; Catteau B; Sans B; Stalder JF; Skowron F; Thomas L; Lorette G; Plantin P; Bordigoni P; Lortholary O; de Prost Y; Moussy A; Sobol H; Dubreuil P
J Invest Dermatol; 2010 Mar; 130(3):804-15. PubMed ID: 19865100
[TBL] [Abstract][Full Text] [Related]
35. CNS germinomas are characterized by global demethylation, chromosomal instability and mutational activation of the Kit-, Ras/Raf/Erk- and Akt-pathways.
Schulte SL; Waha A; Steiger B; Denkhaus D; Dörner E; Calaminus G; Leuschner I; Pietsch T
Oncotarget; 2016 Aug; 7(34):55026-55042. PubMed ID: 27391150
[TBL] [Abstract][Full Text] [Related]
36. Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation.
Zuluaga Toro T; Hsieh FH; Bodo J; Dong HY; Hsi ED
Br J Haematol; 2007 Oct; 139(1):31-40. PubMed ID: 17662084
[TBL] [Abstract][Full Text] [Related]
37. Targeting c-kit in the therapy of mast cell disorders: current update.
El-Agamy DS
Eur J Pharmacol; 2012 Sep; 690(1-3):1-3. PubMed ID: 22789565
[TBL] [Abstract][Full Text] [Related]
38. Combination of KIT gene silencing and tocopherol succinate may offer improved therapeutic approaches for human mastocytosis.
Ruano I; Gargini R; Izquierdo M
Br J Haematol; 2010 Jan; 148(1):59-68. PubMed ID: 19804454
[TBL] [Abstract][Full Text] [Related]
39. Regulation of Reactive Oxygen Species and the Antioxidant Protein DJ-1 in Mastocytosis.
Kim DK; Beaven MA; Kulinski JM; Desai A; Bandara G; Bai Y; Prussin C; Schwartz LB; Komarow H; Metcalfe DD; Olivera A
PLoS One; 2016; 11(9):e0162831. PubMed ID: 27611333
[TBL] [Abstract][Full Text] [Related]
40. SLAMF8 Downregulates Mouse Macrophage Microbicidal Mechanisms
Romero-Pinedo S; Barros DIR; Ruiz-Magaña MJ; Maganto-García E; Moreno de Lara L; Abadía-Molina F; Terhorst C; Abadía-Molina AC
Front Immunol; 2022; 13():910112. PubMed ID: 35837407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
